drugset / Trial / NCT07609225

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225

Phase 0 Not yet recruiting 15 enrolled University of Wisconsin, Madison GE Healthcare · collab
NaSingle-groupOpen-labelTreatment

Summary

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if CSE-MRI is as accurate as FLT PET in telling the difference between active and inactive marrow. The best way to do the comparison between the two imaging procedures is if they are done at the same time on the same patient. This is possible with use of a scanner at the University of Wisconsin Hospitals and Clinics (UW Health), the GE SIGNA PET/MR scanner. The prediction is that CSE-MRI as accurate as FLT at telling the difference between active and inactive marrow in patients with metastatic prostate cancer, and that is the primary reason for this study. 15 participants will be enrolled and on study for up to 14 months.

Timeline

Start
2026-07
Primary completion
2029-07
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FLT Diagnostic / imaging agent 370 mbq Intravenous